- Patients who completed the 13-week treatment of postherpetic neuralgia in Study
- Patients must be able to understand and cooperate with study procedures and have
signed a written informed consent prior to entering the study.
- Patients who experienced serious adverse events in the preceding study (A0081120) that
were determined by the investigator or the study sponsor to be causally related to the
- Patients exhibiting treatment non-compliance in the preceding study (A0081120)